The RAND appropriateness method was used to explore the relevance of risk factors for disease progression in the treatment choice for patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH). A total of, 12 international experts assessed the appropriateness of various treatments for 243 risk profiles. Highest appropriateness rates were found for a 1 -adrenoceptor antagonists (68% of profiles) and combination therapy (46%). A large prostate volume was the dominant argument in favour of 5a-reductase inhibitors and combination therapy, but was irrelevant for the choice of surgery. Considerable postvoid residual, severe symptoms and poor maximum flow rate were the most important factors in favour of surgery.
Introduction
Benign prostatic hyperplasia (BPH) is the most common cause of lower urinary tract symptoms (LUTS) in older men. Although symptoms wax and wane in individual patients and some patients may remain stable or improve, the majority of patients experience symptom deterioration over time. 1, 2 In addition, LUTS/BPH may lead to the development of serious complications such as acute urinary retention (AUR), which usually necessitates invasive treatment. 3 Over the last few years, the focus in managing LUTS/BPH has therefore been widened from short-term symptom relief to durable efficacy, the prevention of serious complications, and the reduction of the risk of invasive treatment. This issue has gained increased attention ever since randomised controlled trials (RCTs) have shown that a 1 -adrenoceptor (AR) antagonists, 5a-reductase inhibitors (RIs) and their combination provide long-lasting symptom relief. 4 Treatment with a 1 -AR antagonists and combination therapy provide the best reduction of symptomatic progression, while 5a-RIs and combination therapy reduce the risk of AUR and the need of invasive treatment to the largest extent, in particular in high-risk patients. 4 From a clinical point of view, it is therefore important to identify patients who are at high risk for progression and to treat them accordingly. Epidemiological surveys and RCTs have identified a number of clinical variables that are associated with an elevated risk of progression. [4] [5] [6] [7] [8] [9] [10] These include age, prostate volume, prostate-specific antigen (PSA), symptom severity, maximum flow rate (Q max ), and postvoid residual (PVR). [4] [5] [6] [7] [8] [9] [10] However, since the available evidence is derived from epidemiological surveys or RCTs and often concerns the impact of single risk factors, their results are difficult to translate to the decision-making process in daily clinical practice.
Recently, we described a study in which a panel of experts developed a risk classification based on the combination of various clinical variables. 11 In this article, we report on the panellists' opinions on the relationship between this risk classification and appropriateness of treatment choice for patients with LUTS/BPH.
Methods
We used the RAND appropriateness method (RAM), 12 which is a modified Delphi approach. The RAM has been applied to determine the appropriateness of medical and surgical procedures in various fields of medicine. 13 It provides a structured approach to combine best evidence from clinical studies with the collective judgement of experts. 12, 13 Firstly, a literature review of studies identifying factors related to LUTS/BPH progression and assessing the impact of (medical) therapies on long-term symptom improvement, the occurrence of AUR and the need for invasive treatment was performed.
14 The literature review included epidemiological surveys, RCTs, as well as published results from questionnaires evaluating the opinion of urologists with regard to risk factors and the impact of therapy on LUTS/BPH progression. The literature review, accompanied by a questionnaire on the relevance of risk factors for treatment decisions in day-to-day care and appropriate cutoff points/categories, was sent to a panel of 12 urologists from eight countries in Europe, North America and South America. Based on their answers, six potentially relevant risk factors (age, symptoms, prostate volume, PSA, Q max and PVR) and cutoff points/ categories were combined to form 324 unique risk/ patient profiles. The panel then convened in August 2003 to individually rate the appropriateness of several common treatments for LUTS/BPH for all risk profiles against a reference treatment (ie a 1 -AR antagonist continuously), using an electronic rating program. After data analysis, the panel discussed the results and methods used. The discussion revealed that age could be excluded from further considerations because it proved not to be associated with the appropriateness assessments. The results also showed that an a 1 -AR antagonist continuously was considered appropriate for 51% of cases vs 7% for the alternative treatments. 15 However, instead of comparing the seven alternative treatments vs a 1 -AR antagonist continuously as the reference therapy, it was preferred to make a comparison between all treatments, by attributing absolute 'marks' for appropriateness (9-points scale) for all treatments included. In addition, the panel suggested some changes to the definitions and cutoff points used (Table 1) . After the meeting, panel members were provided with the revised electronic rating program, which they completed at home. In the second rating round, panellists assessed the appropriateness of seven LUTS/BPH treatments ( Table 1) for 243 risk profiles, using the adapted electronic rating program ( Figure 1 ). These profiles were unique combinations of the values of five clinical variables considered most relevant by the panel in the first rating round: symptoms (total International Prostate Symptom Score (I-PSS); categories: 0-7, 8-19, 20-35), prostate volume (o30, 30-59, X60 ml), PSA (o1.4, 1.4-3.9, X4.0 ng/ml), Q max (415, 10-15, o10 ml/s) and PVR (o50, 50-150, 4150 ml). The extent of appropriateness (benefit/ risk assessment) 12 of the treatments was expressed using a 9-point scale (9 ¼ excellent/very appropriate, 5 ¼ neither appropriate nor inappropriate, 1 ¼ very poor/ very inappropriate). In addition, panellists attributed a risk score for progression ranging from 1 (very low) to 5 (very high) for each of the 243 risk/patient profiles. Appropriateness statements (appropriate, uncertain, inappropriate) were calculated based on the median score and the extent of agreement between panellists, following typical rules used in most other RAM panel studies. 16 For a median score between 7 and 9 without disagreement, the treatment was considered appropriate. For a median score between 1 and 3 without disagreement, the treatment was called inappropriate. All other outcomes were labelled as uncertain. Frequency tables and cross tabulations were used to summarise the results on agreement and appropriateness judgements. The relationship between clinical variables and panel statements was analysed using logistic regression techniques.
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Results
Agreement and appropriateness
The figures for agreement and appropriateness of the various treatments are summarised in Table 2 . Disagreement (opposite opinions among the panel members) was seen for only 10% of all ratings, and was highest for combination therapy and invasive treatments. The highest appropriateness rate was found for a 1 -AR antagonists (68% of profiles), followed by combination therapy (46%). For plant extracts and minimally invasive treatments, no appropriate profiles were found. Plant extracts and watchful waiting had the highest rates for Figure 1 User interface of the electronic rating program. Appropriateness of LUTS/BPH treatment M Speakman et al inappropriateness, while uncertainty was most frequently seen for minimally invasive treatments and 5a-RIs.
Relationship between risk factors and appropriateness ratings
To identify specific profiles for which the treatments were considered appropriate, we performed logistic regression analysis with the outcome 'appropriate' (yes/no) as the dichotomous dependent variable. As explanatory variables, we included all risk factors. Plant extracts and minimally invasive treatments were excluded from the analyses because no appropriate profiles were found for these options. Regression coefficients are shown in Table 3 . The values are calculated in comparison with a reference patient, having no unfavourable conditions (total I-PSS 0-7, prostate volume o30 ml, PSAo1.4 ng/ ml, Q max 415 ml/s, PVRo50 ml). The magnitude of the relative contribution of the various risk factors has to be related to the constant value for each of the treatments considered (a constant value of zero represents a 50% probability that the treatment is considered appropriate).
Because it is impossible to present the appropriateness values of all treatments for all 243 patient profiles, we summarised the principal outcomes using a probability profile in which the simultaneous impact of the different risk factors on the appropriateness ratings is illustrated ( Figure 2 ). This figure shows the probability (based on the regression models) that the panel would rate a certain treatment indication appropriate if the ratings were carried out a second time. Watchful waiting was considered appropriate for patients with no or few risk factors. Considerable PVR, severe symptoms and poor Q max were the dominant factors in favour of surgery. Treatment with an a 1 -AR antagonist showed high appropriateness rates for most profiles between these extreme profiles. The appropriateness of combination therapy increased with the number of risk factors, particularly in patients with a large prostate volume. A large prostate volume (X60 ml) did not exclusively determine the appropriateness of surgery. The impact of PSA on the appropriateness ratings was almost absent. Figure 2 Example of the simultaneous impact of various risk factors on the appropriateness ratings. Probabilities are based on logistic regression.
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Risk score and appropriateness of therapy There were strong associations (Spearman's rho: R s ) between the mean risk score of progression (using the 5-point scale: 1 ¼ very low, 5 ¼ very high) and mean appropriateness ratings for the respective treatments. Strong negative coefficients were seen for watchful waiting (R s ¼ À0.80) and plant extracts (R s ¼ À0.74), and a strong positive correlation existed for surgery (R s ¼ 0.91), minimally invasive treatments (R s ¼ 0.81), and combination therapy (R s ¼ 0.61). For 5a-RIs, the correlation was weak (R s ¼ 0.22). A statistically significant correlation was absent for a 1 -AR antagonists, which can be attributed to the high proportion of risk profiles for which this type of medication was considered appropriate (68%).
The relationship between risk score and appropriateness of treatment is further illustrated by the percentage of appropriate profiles according to risk category (Table 4 ). An a 1 -AR antagonist was considered more frequently appropriate than other regimens in patients with an intermediate-risk score (2-4), combination therapy in patients with an intermediate-high-risk score (3) (4) (5) and surgery in patients with a high-risk score (4) (5) .
Discussion
This study represents the first attempt to apply a systematic methodology for combining best evidence with expert opinion in considering risk factors for disease progression in the day-to-day management of LUTS/BPH. From the variables included, the panel considered symptom severity, prostate volume, Q max and PVR as the most important factors guiding treatment choice in the light of potential disease progression. In contrast to the findings of epidemiological and clinical studies, 10 age and PSA were considered as being less relevant for treatment choice in daily practice. This may be due to the fact that age is strongly correlated with (the severity of) LUTS, but that symptoms (and not age as such) form the reason for initiating therapy. In addition, there is a strong correlation between PSA and prostate volume in LUTS/BPH patients. 17 Obviously, the panel considered prostate volume as a more 'direct' risk factor for progression, having more significance for treatment choice.
The results showed distinct risk profiles for which particular treatments were considered appropriate, and others were not. For patients with mild symptoms and no or only few other unfavourable conditions, watchful waiting was most frequently considered as the appropriate strategy. For the majority of the theoretical patients, particularly in those with an intermediate-risk score (2-4) , an a 1 -AR antagonist as monotherapy was favoured more often than other regimens. Combination therapy was particularly considered appropriate in patients with an increased prostate volume (X30 ml) and an intermediate-high-risk score (3) (4) (5) . Monotherapy of an a 1 -AR antagonist for the vast majority of LUTS/ BPH patients and adding a 5a-RI in patients with a large prostate volume/high PSA is also the recommended treatment approach by, for instance, the American Urological Association. 18, 19 This recommendation is mainly based on the results of the MTOPS trial. 4 Although the present study was performed before the MTOPS results were fully published, urologists seem to agree that this is also a useful approach in clinical practice for these patient profiles. It is recognised that all the risk factors for progression are dynamic factors and that these may change during initial treatment of LUTS/ BPH. The expert panel was asked to judge the treatment choice solely on the basis of the information provided in the 243 patient profiles. Surgery was mainly preferred in patients with a high-risk score (4-5), predominantly due to severe symptoms, a high PVR and/or a poor Q max .
Comparison of our results with those of two previously conducted RAM studies on the appropriateness of LUTS/BPH treatments [20] [21] [22] suggests a reduction in the percentage of patients for whom surgery is indicated. In relation to our panel ratings for combination therapy (not included in the earlier panel studies), these figures may reflect the emerging role of combination therapy as a substitute for immediate invasive therapy.
Our results were based on a systematic and transparent methodology combining best external evidence with the collective judgements of an international panel. However, only a clinical study could show that compliance with the panel recommendations would indeed lead to better patient outcomes. Note that several treatments may be appropriate for the same risk profile.
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